Navigation Links
Ventana receives approval from China's FDA for first fully automated IHC companion diagnostic identifying ALK protein expression in lung cancer patients
Date:9/11/2013

TUCSON, Ariz., Sept. 11, 2013 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced the approval of the VENTANA ALK immunohistochemistry (IHC) assay by the Chinese Food and Drug Administration (CFDA) as a companion diagnostic to aid in the identification of patients for Pfizer's CFDA-approved oncology product XALKORI® (crizotinib). The VENTANA ALK (D5F3) Rabbit Monoclonal Primary Antibody assay is designed to identify ALK-positive patients in non-small cell lung cancer (NSCLC) patients1. The approval is based on a retrospective study that included 1100 Chinese subjects across three national hospitals where the VENTANA assay demonstrated 99.23 percent concordance with Abbott's Vysis ALK Break Apart FISH Probe Kit.

Lung cancer is the leading cause of cancer-related death worldwide and in China, with NSCLC being the most common sub-type.  One important biomarker in NSCLC is the anaplastic lymphoma kinase (ALK) fusion gene, which is associated with pathologic expression of an ALK fusion protein. The detection of ALK positivity is very important for NSCLC patients because inhibition of the ALK tyrosine kinase has led to tumor shrinkage for ALK-positive patients.  XALKORI® is an oral first-in-class ALK inhibitor that has been shown to block important growth and survival pathways which may shrink or slow the growth of tumors.  It  is indicated for the treatment of locally advanced or metastatic ALK-positive NSCLC.

"I am delighted with the successful product registration of ALK IHC in China," says Fatt Heng Wong, GM, Roche Diagnostics China.  "It allows us to offer our customers ALK diagnostic testing in non-small cell lung cancer—one of the most prevalent and deadly cancers in China—as part of our active pursuit of Personalized Healthcare initiatives through new innovative products."

The VENTANA ALK IHC companion diagnostic assay, available in over 53 countries, provides patients and lab professionals a highly efficient, standardized, and cost effective testing method for the assessment of ALK protein expression. In addition, the VENTANA ALK IHC assay is the only CE-marked IVD IHC test with a claim to identify patients eligible for XALKORI treatment. IHC interpretation using brightfield microscopy is widely accessible on over 4,000 VENTANA BenchMark XT and GX instruments globally.  Immunohistochemistry offers fast interpretation, seamless integration into lab workflow and the ability to archive test results.

"Approval of the VENTANA ALK assay in China is a tremendous accomplishment and will provide physicians and patients a best-in-class and cost effective method to identify ALK protein expression. With the world's largest installed base of IHC automated staining instruments and industry-leading pipeline of companion diagnostics, Ventana is positioned to create significant benefits for patients, physicians, laboratories and payers worldwide," says Doug Ward, Vice President, Companion Diagnostics, Ventana Medical Systems, Inc.

The VENTANA ALK assay approval by the CFDA highlights the global strength of Roche Diagnostics.  Ventana closely collaborates with Roche country affiliates, such as Roche Diagnostics China, to complete clinical studies and register IVD products upon approval in countries worldwide.  In addition to Pfizer, Ventana has worked with more than 45 biopharmaceutical partners over the past decade and is currently engaged in over 150 collaborative projects to develop and commercialize companion diagnostics globally.

"The success of our collaboration with Pfizer in developing the ALK IHC assay exemplifies our strategy to enable Personalized Healthcare for patients worldwide and our commitment to be Pharma's Partner of Choice," says Mara G. Aspinall, President, Ventana Medical Systems, Inc.

About Ventana Medical Systems, Inc.
Ventana Medical Systems, Inc. ("VMSI") (SIX: RO, ROG; OTCQX: RHHBY), a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA solutions are used in clinical histology and drug development research laboratories worldwide. The company's intuitive, integrated staining, workflow management platforms, and digital pathology solutions optimize laboratory efficiencies to reduce errors, support diagnosis and inform treatment decisions for anatomic pathology professionals. Together with Roche, VMSI is driving Personalized Healthcare through accelerated drug discovery and the development of "companion diagnostics" to identify the patients most likely to respond favorably to specific therapies.

VENTANA, the VENTANA logo, and BenchMark are trademarks of Roche.

Visit http://ventana.com/ to learn more.

1The VENTANA ALK (D5F3) Rabbit Monoclonal Primary Antibody assay is not approved in the U.S. and is currently for investigational use only.

 

Related Links
BenchMark XT

Image with caption: "Positive Case of lung tissue stained for ALK." Image available at: http://photos.prnewswire.com/prnh/20130911/MM77371-a

Image with caption: "Negative Case of lung tissue stained for ALK." Image available at: http://photos.prnewswire.com/prnh/20130911/MM77371-b

Image with caption: "VENTANA BenchMark XT." Image available at: http://photos.prnewswire.com/prnh/20130911/MM77371-c

VMSI Media Relations
Jacqueline Bucher
Senior Director, Corporate Communications
Phone: 520-877-7288
e-mail: jacquie.bucher@ventana.roche.com


'/>"/>
SOURCE Ventana Medical Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ventana Receives FDA Clearance for p53 (DO-7) Image Analysis and Digital Read Applications
2. Ventana licenses Gen-Probe IP for measuring ERG protein in prostate cancer patients
3. Ventana Supports World Patient Safety Day, July 25
4. Ventana Medical Systems, Inc. develops first-ever fully automated dual-stain technique for miRNA and protein detection in cancer
5. MedeAnalytics Receives Leadership Award from Ventana Research
6. Ventana and Biocare Medical sign p63 license agreement to aid in the differential diagnosis of benign and malignant prostate lesions
7. Ventana and Barco revolutionize digital pathology viewing experience
8. Ventana and EMC join forces to take digital pathology into the world of Big Data
9. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
10. Leica Biosystems Receives FDA Approval for the Fully Automated Bond Oracle™ HER2 IHC System on the Leica BOND-MAX
11. Nephros Receives 510(k) Clearance for Hemodiafiltration System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)...  Caris Life Sciences ® , a leading innovator ... precision medicine, today announced that St. Jude Medical Center,s ... (POA) as its 17 th member. Through participation ... Cancer Institute will help develop standards of care and ... making cancer treatment more precise and effective. ...
(Date:10/10/2017)... EXTON, Pa. , Oct. 10, 2017   ... leader in innovative solutions for injectable drug administration, today ... of West,s ID Adapter for improving the intradermal administration ... the Fourth Skin Vaccination Summit in May 2017 by ... Team Lead, Polio Department, World Health Organization (WHO), and ...
(Date:10/4/2017)... , Oct. 4, 2017  According to the Centers for Disease ... end of October . PhysicianOne Urgent Care is helping communities across ... Westchester, NY , by offering no-cost* flu shots through the end ... mandated by certain health insurance regulations. ... The best time to get a flu shot is by the end ...
Breaking Medicine Technology:
(Date:10/13/2017)... New York, NY (PRWEB) , ... October 13, 2017 , ... ... most influential people in business to advocate for action towards gender equality at their ... 18,000 views from around the globe, and reached a social audience of over 3 ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, ... lowdown on sciatica in a new episode of "Success Files," which is an ... and innovation and investigates each subject in-depth with passion and integrity. , Sciatica ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of ... Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, ... In honor of Morris F. Collen, a pioneer in the field of medical informatics, ...
Breaking Medicine News(10 mins):